Singapore markets closed
  • Straits Times Index

    3,194.04
    +6.26 (+0.20%)
     
  • Nikkei

    29,020.63
    -167.54 (-0.57%)
     
  • Hang Seng

    29,078.75
    +323.41 (+1.12%)
     
  • FTSE 100

    6,938.56
    +0.32 (+0.00%)
     
  • BTC-USD

    49,866.46
    -5,104.18 (-9.29%)
     
  • CMC Crypto 200

    1,143.28
    +19.38 (+1.72%)
     
  • S&P 500

    4,182.79
    +47.81 (+1.16%)
     
  • Dow

    34,041.00
    +225.10 (+0.67%)
     
  • Nasdaq

    14,032.43
    +214.02 (+1.55%)
     
  • Gold

    1,777.30
    -4.70 (-0.26%)
     
  • Crude Oil

    61.91
    +0.48 (+0.78%)
     
  • 10-Yr Bond

    1.5610
    +0.0070 (+0.45%)
     
  • FTSE Bursa Malaysia

    1,608.43
    +0.70 (+0.04%)
     
  • Jakarta Composite Index

    6,016.86
    +22.68 (+0.38%)
     
  • PSE Index

    6,378.07
    -37.46 (-0.58%)
     

Cullinan Oncology, Inc. to Participate in the H.C. Wainwright Global Life Sciences Conference

Cullinan Management, Inc.
·1-min read

CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies, today announced that the company’s Chief Executive Officer, Owen Hughes, will present at the upcoming H.C. Wainwright Global Life Sciences Conference.

Event: H.C. Wainwright Global Life Sciences Conference
Date: Tuesday, March 9th
Time: 7:00am EST
Location: Virtual

The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7am EST on Tuesday, March 9th, 2021, for registered attendees only.

About Cullinan Oncology

Cullinan Oncology is a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies. The Company’s strategy is to build a pipeline of therapeutic candidates that are uncorrelated across multiple dimensions, with a focus on assets that it believes have novel technology, employ differentiated mechanisms, are in a more advanced stage of development than competing candidates, or have a combination of these attributes.

Contacts:

Investor Relations
investors@cullinanoncology.com

Jeff Trigilio
+1 716.725.5019
jtrigilio@cullinanoncology.com